Bone loss due to osteoclastic activity.
| Excerpt | Reference |
|---|
| "These results, that bone resorption is reduced in microphthalmic mice, are discussed in relation to the pathogenesis and cure of the disease." | ( Marks, SC, 1977) |
| "Bone resorption is a multistep process that includes the maturation of osteoclast precursors, the special attachment of fully differentiated osteoclasts to mineralized bone surface, and the dissolution of inorganic mineral, as well as the breakdown of organic matrix." | ( Hentunen, TA; Lakkakorpi, PT; Rautiala, T; Väänänen, HK, 1991) |
| "Osteoclastic bone resorption is activated by 7 days of oral neutral phosphate and inhibited with a brief pulse (5 days) of etidronate disodium at a high dose (20 mg/kg body weight)." | ( LeBlanc, AD; Mallette, LE; Mechanick, JI; Pool, JL, 1989) |
| "Bone resorption is also a feature of many systemic diseases, some of which can affect the alveolar bone." | ( Pierce, A, 1989) |
| "However, since bone resorption is quantitatively more stimulated than bone formation, the physiological bone loss is accelerated and is only partly repaired by re-establishment of the normal thyroid function." | ( Lalau, JD; Quichaud, J; Sebert, JL, 1985) |
| "Bone resorption is a common finding in chronic otitis media with or without cholesteatoma." | ( Juhn, SK; Jung, TT, 1988) |
| "This inhibition of bone resorption is discussed in relation with the collagen-stabilizing properties of (+)-catechin." | ( Delaissé, JM; Eeckhout, Y; Vaes, G, 1986) |
| "Bone resorption is modulated by parathyroid hormone, 1,25-dihydroxyvitamin D and other hormones." | ( Trechsel, U, 1986) |
| "Although bone resorption is central to this syndrome, the mechanism of resorption is uncertain." | ( Adler, M; Broadus, AE; Byers, CM; Segre, GV; Stewart, AF, 1982) |
| "This stimulation of bone resorption is accompanied by an inhibition of the incorporation of [3H]proline into collagen which is independent of increased prostaglandin production by the bone." | ( Beresford, JN; Couch, M; Gallagher, JA; Gowen, M; Poser, J; Russell, RG; Wood, DD, 1984) |
| "Spontaneous bone resorption is reduced in cultured calvarial bones from mice with the Chediak-Higashi syndrome, as indicated by decreased mobilization of calcium from the bones to the medium." | ( Gustafson, GT; Lerner, U; Ransjö, M, 1981) |
| "Bone resorption is a significant component of chronic inflammatory ear disease." | ( Gantz, BJ; Maynard, J, 1982) |
| "The inhibition of bone resorption is dose dependent and reversible within the first 24 h of treatment." | ( Krieger, NS; Tashjian, AH, 1980) |
| "A critical step in bone resorption is the fusion of mononuclear osteoclast precursors to form multinucleated osteoclasts." | ( Boyce, BF; Chen, H; Mbalaviele, G; Mundy, GR; Yoneda, T, 1995) |
| "Excessive bone resorption is attributed to hyperparathyroidism which is secondary to calcium malabsorption." | ( Adami, S; Rossini, M, 1993) |
| "Osteoclastic bone resorption is modulated in humans by powerful osteotropic factors which are generated in the immediate vicinity of bone resorbing surfaces." | ( Mundy, GR, 1993) |
| "6." | ( Alam, AS; Bax, BE; Bax, CM; Bevis, PJ; Blake, DR; Moonga, BS; Pazianas, M; Shankar, VS; Stevens, C; Zaidi, M, 1993) |
| "However, bone resorption is essential for the healing of fractures, the repair of microscopic fatigue cracks in bone, nad the internal reorientation of trabecular and cortical bone in response to altered mechanical strains." | ( Neer, RM, 1995) |
| "Bone resorption is known to parallel bone formation, and thus in the present study we looked for racial differences in bone turnover in children by measuring the nocturnal urinary excretion of three markers of bone resorption: hydroxyproline and the pyridinium cross-links, pyridinoline and deoxypyridinoline." | ( Manatunga, AK; Peacock, M; Pratt, JH, 1996) |
| "A key event in bone resorption is the recruitment of osteoclasts to future resorption sites." | ( Blavier, L; Delaissé, JM, 1995) |
| "Enhanced bone resorption is a characteristic finding in multiple myeloma (MM)." | ( Apperley, J; Girgis, S; Nawawi, H; Samson, D, 1996) |
| "Osteoclast bone resorption is essential for normal calcium homeostasis and is therefore tightly controlled by calciotropic hormones and local modulatory cytokines and factors." | ( Anderson, F; Collin-Osdoby, P; Jiang, X; Kirsch, D; Osdoby, P; Rothe, L; Sunyer, T, 1997) |
| "Because bone resorption is especially active at night, the Ca/OSM ratio in sleep urine may be the most sensitive marker of bone resorption." | ( Fujii, Y; Fujita, T; Ohgitani, S, 1997) |
| "The best indices of bone resorption are the new immunoassays for pyridinoline cross-links and type I collagen-related peptides in urine and, recently, in serum." | ( Delmas, PD; Garnero, P, 1998) |
| "This increased bone resorption is inhibited by pamidronate without reducing G-CSF-induced HPC mobilization, suggesting that the activation of bone resorption after G-CSF administration is not the direct cause of HPC mobilization as initially hypothesized, but a parallel event." | ( Lévesque, JP; Moore, RJ; Morris, HA; Simmons, PJ; Takamatsu, Y; To, LB, 1998) |
| "It is known that bone resorption is mediated by osteoclasts, and lipopolysaccharide (LPS) and inflammatory mediators such as interleukin-1 (IL-1) and prostaglandin E2 (PGE2) induce osteoclast differentiation from haemopoietic cells, 2-aminoethanesulphonic acid, which is known as taurine, is an important nutrient and is added to most synthetic human infant milk formulas." | ( Ishihara, Y; Kaneko, K; Kazuno, K; Koide, M; Nishihara, T; Noguchi, T; Ohguchi, M; Okahashi, N; Shibasaki, K; Tanaka, R; Ueda, N; Yamazaki, Y, 1999) |
| "Bone resorption is regulated by the cytokines within marrow cells that mediate osteoclast formation and activation." | ( Tani-Ishii, N; Teranaka, T; Tsunoda, A; Umemoto, T, 1999) |
| "Markers of bone resorption are sensitive to changes in bone turnover induced by treatment." | ( Delmas, PD; Fontana, A, 2000) |
| "Bone resorption is the unique function of the osteoclast, and anti-osteoporosis therapy to date has targeted this cell." | ( Teitelbaum, SL, 2000) |
| "Bone resorption is regulated by the immune system, where T-cell expression of RANKL (receptor activator of nuclear factor (NF)-kappaB ligand), a member of the tumour-necrosis factor family that is essential for osteoclastogenesis, may contribute to pathological conditions, such as autoimmune arthritis." | ( Chiba, T; Hida, S; Murata, S; Nakamura, K; Oda, H; Ogasawara, K; Sato, K; Takaoka, A; Takayanagi, H; Tanaka, K; Taniguchi, T; Yokochi, T, 2000) |
| "Bone resorption is carried out by osteoclasts, which are formed by fusion of circulating mononuclear precursor cells of haematopoietic origin." | ( Athanasou, NA; Fujikawa, Y; Hirayama, T; Jevon, M; Neale, SD; Sabokbar, A; Wass, J, 2002) |
| "Bone resorption is glucose concentration dependent." | ( Falany, ML; Larsen, KI; Ponomareva, LV; Wang, W; Williams, JP, 2002) |
| "Bone resorption is one of the hallmarks of inflammatory periapical lesions and is mediated by cytokines." | ( Klein, A; Klein, H; Metzger, Z; Tagger, M, 2002) |
| "In conclusion, bone resorption is suppressed in the luteal phase through a mechanism that does not involve increases in serum OPG." | ( Abrahamsen, B; Beck-Nielsen, H; Bonnevie-Nielsen, V; Rettmer, E; Stilgren, LS, 2003) |
| "Bone resorption is caused by osteoclasts." | ( Aspenberg, P; Astrand, J; Skoglund, B; Skripitz, R, 2003) |
| "Bone resorption is carried out by osteoclasts." | ( Athenasou, NA; Brown, MA; Hirayama, T; Jevon, M; Ostelere, S; Sabokbar, A; Wass, JA, 2003) |
| "Bone resorption is closely dependent on osteoclastic survival and osteoclast apoptotic cell death could represent a key step at the end of this process." | ( Brazier, M; Kamel, S; Mentaverri, R, 2003) |
| "Bone resorption is increased in women with knee OA, consistent with metabolically active subchondral bone." | ( Bettica, P; Hart, D; Hunter, DJ; Snieder, H; Spector, TD; Swaminathan, R, 2003) |
| "Bone resorption is uncoupled from bone formation, contributing to the bone loss." | ( Bikle, DD; Halloran, BP; Sakata, T, 2003) |
| "Bone resorption is most sensitive to changes in H+ concentration at a pH of about 7." | ( Arnett, T, 2003) |
| "Osteoclastic bone resorption is a common finding of otitis media with or without cholesteatoma." | ( Sohn, SJ, 2005) |
| "Bone resorption is increased, whereas bone formation is decreased." | ( Iwamoto, J; Sato, Y; Takeda, T, 2005) |
| "The bone resorption is not caused by renal insufficiency, hyperparathyroidism, or steroid therapy." | ( Bergstrom, WH; Blystone, LW; Welch, TR, 2005) |
| "Bone resorption is dependent on the liberation of calcium by acid and protease destruction of the bone matrix by proteinases." | ( Day, CJ; Morrison, NA; Selinger, CI, 2005) |
| "Bone resorption is believed to be a complicated molecular reaction process that occurs in the microcircumstance of bone tissue." | ( Deng, X; Pan, J; Wang, Y; Zhang, B; Zhao, J, 2005) |
| "Bone resorption is commonly associated with aging and with certain types of cancer, including multiple myeloma and breast cancer." | ( Aggarwal, BB; Ichikawa, H, 2006) |
| "Osteoclastic bone resorption is enhanced in Opg(-/-) mice lacking osteoprotegerin, which is a soluble decoy receptor for the osteoclastogenic cytokine RANKL." | ( Ito, M; Kanzaki, S; Matsuo, K; Ogawa, K; Takada, Y, 2006) |
| "Bone resorption is believed to be responsible for osteolytic metastasis." | ( Amizuka, N; Li, M, 2006) |
| "Peri-articular bone resorption is a feature of arthritis due to crystal deposition and rheumatoid disease." | ( Adamopoulos, IE; Athanasou, NA; Danks, L; Ferguson, DJ; Itonaga, I; Locklin, RM; Sabokbar, A, 2006) |
| "The risk of bone resorption is greater in early years than late years of menopause." | ( Naidu, DM; Suresh, M, 2006) |
| "Osteoclast bone resorption is known to be dependent on the expression of the tyrosine kinase, c-Src." | ( Cohen, C; Edwards, JC; Schlesinger, PH; Xu, W, 2006) |
| "Intense bone resorption is a natural phenomenon also observed in some teleosts, during reproductive migration and fasting." | ( Aroua, S; Baloche, S; Dufour, S; Kacem, A; Lopez, E; Meunier, F; Rousseau, K; Sbaihi, M, 2007) |
| "Alveolar bone resorption is a characteristic feature of periodontal diseases and involves removal of both the mineral and the organic constituents of the bone matrix, a process mainly carried out by multinucleated osteoclast cells." | ( Chai, JK; Cho, KS; Choi, SH; Kim, CK; Kim, CS; Yun, JH, 2007) |
| "Osteoclastic bone resorption is a central mechanism in skeletal development, remodeling and pathology." | ( Battaglino, R; Fu, J; Schulze-Späte, U; Sharma, A; Stashenko, P; Vokes, M, 2007) |
| "Osteoclastic bone resorption is a critical component of skeletal complications of malignancy including fracture, bone pain, hypercalcemia, and spinal cord compression." | ( Dougall, WC; Roodman, GD, 2008) |
| "Bone resorption is known to accelerate during the onset of several disorders, including osteoporosis (OP) and rheumatoid arthritis (RA)." | ( Katsumata, S; Murakami, A; Ohigashi, H; Song, M; Suzuki, K; Uehara, M, 2007) |
| "Bone resorption is mainly carried out by a specific type of cell called the osteoclast (OCL)." | ( Akiyama, T; Choong, PF; Dass, CR; Kawano, H; Shinoda, Y; Tanaka, S, 2010) |
| "Bone deposition and bone resorption are ongoing dynamic processes, constituting bone remodeling." | ( de Seixas Alves, MT; Filho, RJ; Macedo, CR; Okamoto, OK; Oliveira, ID; Petrilli, AS; Toledo, SR; Zago, MA, 2010) |
| "Given that bone resorption is exceeding bone formation, a reduction in bone mass leads to disease conditions including post-menopausal osteoporosis and tumor-induced osteolysis." | ( Masuya, K; Teno, N, 2010) |
| "The control of bone resorption is crucial in osteolytic diseases." | ( Colombatti, A; Pivetta, E; Scapolan, M; Spessotto, P; Steffan, A; Wassermann, B, 2011) |
| "Bone resorption is dependent on a cytokine known as RANKL (receptor activator of NF-κB ligand)." | ( Cai, Y; Wang, YN; Zhao, Y, 2010) |
| "Because bone resorption is an essential requirement for adequate remodeling during fracture healing, we conclude that melatonin impairs fracture healing by suppressing bone resorption through down-regulation of RANKL-mediated osteoclast activation." | ( Anton, C; Garcia, P; Histing, T; Holstein, JH; Klein, M; Matthys, R; Menger, MD; Pohlemann, T; Scheuer, C, 2012) |
| "Bone resorption is regulated by various cytokines." | ( Inada, M; Miyaura, C, 2010) |
| "Excessive bone resorption is involved in the pathogenesis of bone-related disorders such as osteoporosis, arthritis and periodontitis." | ( Asai, M; Cha, BY; Hasegawa, S; Nagai, K; Ninomiya, T; Ozawa, H; Sasaki, T; Teruya, T; Woo, JT; Yagasaki, K; Yonezawa, T, 2011) |
| "Increased bone resorption is a noncell autonomous defect, caused by exuberant stimulation of osteoclastogenesis by Cx43-deficient bone marrow stromal cells, via decreased Opg production." | ( Beniash, E; Civitelli, R; Grimston, SK; Guillotin, B; Norris, JY; Shaw, A; Watkins, M, 2011) |
| "Bone resorption is suggested to occur, at least in part, through the increased levels of two proteolytic enzymes, MMP-2 and MMP-9, and RANKL, which are mainly produced by osteoblasts." | ( Caron, J; Martel-Pelletier, J; Mineau, F; Pelletier, JP; Tat, SK, 2011) |
| "Bone resorption is primarily treated with bisphosphonates, which are associated with highly undesirable side effects, including nephrotoxicity and osteonecrosis of the jaw." | ( Bloom, AP; Chandramouli, A; Ferland, HL; Hanlon, KE; Havelin, JJ; Jimenez-Andrade, JM; King, T; Largent-Milnes, TM; Lozano-Ondoua, AN; Mantyh, PW; Nelson, MA; Nikolich-Zugich, T; Owusu-Ankomah, M; Porreca, F; Symons-Liguori, AM; Vanderah, TW, 2013) |
| "Inhibition of bone resorption is fully reversible following discontinuation." | ( Josse, R; Khan, A; Ngui, D; Shapiro, M, 2013) |
| "Bone resorption is reduced by increased synthesis of osteoprogeterin (OPG), a decoy receptor that prevents receptor activator of NK-κB ligand (RANKL) in binding to its receptor." | ( Amstrup, AK; Mosekilde, L; Rejnmark, L; Sikjaer, T, 2013) |
| "Bone resorption is the unique function of osteoclasts (OCs) and is critical for both bone homeostasis and pathologic bone diseases including osteoporosis, rheumatoid arthritis and tumor bone metastasis." | ( Dai, K; Fan, Q; Li, H; Liu, G; Liu, X; Ouyang, Z; Qin, A; Qu, X; Tang, T; Wu, C; Zhai, Z, 2014) |
| "Bone resorption is known to be involved in both osteolytic and osteoblastic bone metastasis." | ( Aikawa, T; Hoshino, T; Kadonosono, T; Kizaka-Kondoh, S; Kobayashi, T; Kuchimaru, T; Yasuda, H, 2014) |
| "Because bone resorption is largely unaltered, OSM could represent a new anabolic treatment for unconsolidated bone fractures." | ( Amiaud, J; Berreur, M; Blanchard, F; Boutet, MA; Brounais-Le Royer, B; Gamblin, AL; Guihard, P; Heymann, D; Layrolle, P; Rédini, F; Renaud, A, 2015) |
| "Bone resorption is increased after running, with no change in bone formation." | ( Fraser, WD; Greeves, JP; James, RM; Jones, TW; Sale, C; Tang, JC; Varley, I, 2015) |
| "Bone resorption is increased and bone formation is inhibited in patients with RA, and glucocorticoid negatively affects bone metabolism." | ( Inui, K; Koike, T; Mamoto, K; Nakamura, H; Okano, T; Sugioka, Y; Tada, M, 2016) |
| "In adults, bone resorption is tightly coupled to bone deposition as a means to maintain skeletal homeostasis." | ( Butcher, KD; Curantz, C; Ealba, EL; Hall, J; Jheon, AH; Schneider, RA, 2015) |
| "At the same time, bone resorption is suppressed around titanium sites compared to sham sites after 4 weeks of implantation, suggesting a shift to a more pronounced bone forming environment." | ( Albrektsson, T; Galli, S; Prgomet, Z; Tengvall, P; Trindade, R; Wennerberg, A, 2018) |
| "Low BMD or high bone resorption, are significantly prevalent in these patients." | ( Carvajal, C; Ceballos, ME; Dominguez, A; González, G; Jaramillo, J, 2019) |
| "This increased bone resorption is driven by the hypoxia-inducible transcription factor HIF." | ( Knowles, HJ, 2019) |
| "Pathophysiological bone resorption is commonly associated with periodontal disease and involves the excessive resorption of bone matrix by activated osteoclasts." | ( Hirai, K; Ibaragi, S; Ishii, S; Kobayashi, H; Mandai, H; Nakagawa, S; Nakayama, M; Omori, K; Sakaida, K; Sako, H; Suga, S; Takashiba, S; Yamamoto, S; Yamamoto, T; Yamashiro, K; Yoshimura, H, 2020) |
| "Bone resorption is suppressed acutely in response to glucose and insulin challenges in both healthy subjects and patients with diabetes." | ( Schauer, I; Shah, VN; Sherk, VD, 2020) |
| "The osteoclast bone resorption is critical in aseptic loosening after joint replacement." | ( Liu, W; Qian, Y; Yang, C; Zeng, B; Zhang, X, 2020) |
| Excerpt | Reference |
|---|
| "In most cases bone resorption became normal within a week of treatment, whereas the return to normal bone formation took 3-6 months; this difference produced a transient imbalance between resorption and formation." | ( Bijvoet, OL; Frijlink, WB; Heynen, G; te Velde, J, 1979) |
| "Estrogen therapy does reduce bone resorption and has a definite preventive and curative action whenever there is lack of estrogens." | ( Courrèges, JP; Klotz, HP; Merceron, RE; Raymond, JP, 1979) |
| "The observed changes suggest decreased bone resorption and increased bone formation with deposition of bone mineral after antithyroid treatment." | ( Christensen, MS; Melsen, F; Mosekilde, L; Sørensen, NS, 1978) |
| "The stimulation of bone resorption, assessed by the release of 45Ca from prelabeled bones, was associated with an increase in number of osteoclasts per bone section in parathyroid hormone (PTH)-treated bones, but not in lipopolysaccharide (LPS)-treated bones." | ( Hausmann, E; Rowe, DJ, 1977) |
| "The production of both the bone resorption-stimulating activity and PGE2 was inhibited by more than 90% by treatment of the synovial cultures with indomethacin (5 mug/ml)." | ( Levine, L; Robinson, DR; Tashjian, AH, 1975) |
| "Biochemical parameters reflecting bone resorption [urinary calcium/creatinine (Ca/Cr) and hydroxyproline/creatinine (OH/Cr)] were related to serum estrogens [estrone (E1) and estradiol (E2)] in 262 healthy women including 158 patients receiving estrogen replacement therapy (ERT) for at least 6 months, 49 eugonadal women, and 55 untreated postmenopausal women." | ( Albert, A; Deroisy, R; Franchimont, P; Gaspard, U; Reginster, JY; Sarlet, N, 1992) |
| "Acceleration of bone resorption by PTH-treatment did not change detectably the distribution or intensity of labelling." | ( Karhukorpi, EK; Väänänen, K; Vihko, P, 1992) |
| "Therefore, bone resorption inhibitors like MuIFN-gamma, which ameliorate humoral hypercalcemia without an escape phenomenon, are potentially useful for the treatment of malignancy-associated hypercalcemia." | ( Akatsu, T; Demura, H; Ono, Y; Sato, K; Satoh, T; Shizume, K; Suda, T; Takahashi, N; Yamakawa, Y, 1992) |
| "The influence of chlorthalidone on bone resorption in immobilized patients treated with mechanical ventilation was studied." | ( Duursma, SA; Sangster, B; van Heijst, AN; van Kesteren, RG, 1991) |
| "In an in vivo model of osteoclastic bone resorption, we previously showed that osteocalcin-deficient bone particles (BPs), derived from warfarin-treated rats, were resorbed 50% as well as normal BPs and that they recruited fewer osteoclastic cells with decreased tartrate-resistant acid phosphatase (TRAP) activity." | ( Cox, KA; DeFranco, DJ; Glowacki, J; Lian, JB, 1991) |
| "We determined Ca fluxes of bone resorption and tubular reabsorption in 141 rehydrated patients with hypercalcemia of malignant or benign origin, before any specific treatment." | ( Bonjour, JP; Buchs, B; Rizzoli, R, 1991) |
| "Through inhibition of bone resorption, treatment of OVX rats with 1,25(OH)2D3, 1,24,25(OH)3D3, and the metabolite combination prevented the ovariectomy-induced osteopenia in the lumbar vertebra, and partially prevented cancellous bone osteopenia in the tibial metaphysis." | ( Erben, RG; Kohn, B; Rambeck, WA; Sinowatz, F; Weiser, H, 1990) |
| "The effects of such treatments on bone resorption were assessed by quantitative scanning electron microscopy." | ( Zaidi, M, 1990) |
| "Significant inhibition of bone resorption in each case is seen only after 24-72 h of treatment." | ( Blair, HC; Carano, A; Konsek, JD; Schlesinger, PH; Teitelbaum, SL, 1990) |
| "Rather, the efficacy of CT-impaired bone resorption appeared to be optimal in OVX'd rats treated during the daytime, and least effective during the first half of the environmental dark span." | ( Cornelissen, G; Gundberg, CM; Kidder, L; Lozano, R; Sandstead, E; Simmons, DJ; Thomas, M; Yang, C, 1990) |
| "The simultaneous increase in markers of bone resorption and formation during rhGH treatment followed by a decline in resorption parameters within a few weeks and the prolonged effect on BGP and B-AP demonstrate that rhGH treatment stimulates osteoblasts and activates bone remodeling." | ( Brixen, K; Flyvbjerg, A; Mosekilde, L; Nielsen, HK, 1990) |
| "We attribute evidence of increases in bone resorption and induction of osteopaenia with buserelin treatment to hypo-oestrogenism." | ( Gold, E; Goulding, A, 1989) |
| "Women with increased bone resorption induced by bilateral oophorectomy 1-5 years previously (of a total of 48 women in the study, 20 were controls, and 28 were the treatment group) were studied during a 3 year follow-up." | ( Pacovský, V; Pospíchal, J; Presl, J; Stĕpán, JJ, 1989) |
| "Treated rats had decreased bone resorption: urinary hydroxyproline, plasma acid phosphatase, and the number of osteoclasts in caudal vertebrae were significantly reduced." | ( Bielakoff, J; de Vernejoul, MC; Miravet, L; Modrowski, D; Orcel, P, 1989) |
| "The biochemical indices of bone resorption (urinary hydroxyproline excretion and plasma tartrate-resistant acid phosphatase activity), as well as osteoblastic function (serum osteocalcin and bone alkaline phosphatase isoenzyme), were significantly increased in untreated and insufficiently treated patients compared with treated patients." | ( Musilová, J; Pacovský, V; Stĕpán, JJ, 1989) |
| "The high incidence of metastatic bone resorption in urological cancer makes it necessary for clinicians to look for a valid experimental model to investigate basic interaction between cancer cells and bone in order to improve the treatment." | ( Koiso, K; Nemoto, R; Satoh, T; Tsutsumi, M; Uchida, K, 1988) |
| "Therefore the decrease in bone resorption observed after the administration of gonadal steroids in vivo may at least in part be mediated via stimulation of CT secretion." | ( Bowser, EN; Greenberg, CP; Hargis, GK; Henderson, WJ; Kukreja, SC; Williams, GA, 1986) |
| "Before treatment, bone resorption was greater than normal in all but one patient and bone formation was normal." | ( Jones, JD; Jowsey, J; Kelly, PJ; Maher, FT; Riggs, BL, 1969) |
| "Almost complete inhibition of bone resorption and bone mineralization occurred by 14 days of treatment without effects on skeletal collagen mass." | ( Klein, L; Wong, KM, 1983) |
| "The inhibition of bone resorption is dose dependent and reversible within the first 24 h of treatment." | ( Krieger, NS; Tashjian, AH, 1980) |
| "Similarly, bone resorption in these cultures was inhibited at 24 h by CT treatment, but at 48 and 72 h there was escape from the inhibitory effects of CT on resorption." | ( Goldring, SR; Lee, SK; Lorenzo, JA, 1995) |
| "These results indicate that the bone resorption in children is increased relative to that in adults, that urinary PYR and DPYR levels are increased during puberty when the growth rate is markedly elevated, and that bone resorption in children is accelerated by GH therapy." | ( Fujimoto, S; Kubo, T; Miura, M; Seino, Y; Tanaka, H, 1995) |
| "To test the role of bone resorption in the response of the bone to mechanical stimulation, we compared the anabolic response to a single period of loading, of rats treated with 3-amino-1-hydroxypropylidene-1-bisphosphonate (AHPrBP) or vehicle." | ( Chambers, TJ; Chow, JW; Jagger, CJ, 1995) |
| "The effect of bafilomycin on bone resorption was shown to be very local, and no side effects of treatment with bafilomycin were observed in adjacent teeth or the behavior of dogs." | ( Marks, SC; Sundquist, KT, 1994) |
| "Markers of bone resorption-fasting urinary hydroxyproline/creatinine and calcium/creatinine ratios - and of bone formation-serum alkaline phosphatase and osteocalcin-were determined initially, before the start of treatment and thereafter twice weekly (a total of 17 assessments for each women) during the 8-week treatment period." | ( Balint-Perić, L; Beljić, T; Elliesen, J; Petrović, J; Prelević, GM, 1994) |
| "Bisphosphonates are inhibitors of bone resorption and are used increasingly as therapeutic agents for treating clinical disorders of skeletal metabolism." | ( Bayless, AV; Blackburn, GM; Ebetino, FH; Ji, X; Rogers, MJ; Russell, RG; Watts, DJ; Xiong, X, 1994) |
| "Daily oral treatment with a bone resorption inhibitor, FR78844 (a bisphosphonate compound, 100 mg/kg), for 4 weeks significantly attenuated the osteopenia in the STZ and Ovx rats, but not in the D(-) rats, while 1 alpha-hydroxyvitamin D3 (1 alpha-(OH)D3) significantly attenuated the osteopenia in the STZ and D(-) rats in a dose of 0." | ( Mutoh, S; Takeshita, N; Yamaguchi, I; Yoshino, T, 1994) |
| "In all 24 patients studied, bone resorption (measured by urinary hydroxyproline/creatinine ratio, OHP/Cr) fell sharply on treatment, from 0." | ( Devlin, RD; Fenton, AJ; Grill, V; Gutteridge, DH; Kent, GN; Prince, RL; Retallack, RW; Worth, GK, 1994) |
| "The rate and degree of suppression of bone resorption were monitored in 6 of the patients similarly treated with intravenous dimethyl-APD at a dose of 4 mg/day for 10 days, by daily measurements of the 24 h urinary excretion of Pyr, Dpyr and OHP." | ( Colwell, A; Eastell, R; Hamdy, NA; Papapoulos, SE; Russell, RG, 1993) |
| "The stimulation of bone resorption by hPTHrP-(1-34) and hPTH-(1-34) was equally blocked by either simultaneous treatment with 10(-8) M Elcatonin (eel calcitonin derivative; from Asahi Chemical Industry, Tokyo, Japan) [corrected] or pretreatment with 10(-7) M [Nle8,18Tyr34]hPTH-(3-34)amide." | ( Chihara, K; Fukase, M; Kaji, H; Sugimoto, T, 1993) |
| "Increased bone resorption was present in LIF-treated hemicalvaria compared with that in the noninjected hemicalvaria or calvaria from mice injected with vehicle alone at both 6 and 13 days." | ( Callon, K; Cornish, J; Edgar, S; King, A; Reid, IR, 1993) |
| "Reflecting an increase in bone resorption, 3H-T levels in tibiae and vertebrae were decreased in placebo-treated OVX animals compared to the placebo-treated SO group (p < 0." | ( Bailey, MC; Bain, SD; Celino, DL; Edwards, MW; Jensen, E; Lantry, MM, 1993) |
| "To quantitate bone resorption, the skeletons of fifty 8-week-old Swiss-Webster mice were prelabeled with [3H]tetracycline (3H-T) before initiation of treatment protocols." | ( Bailey, MC; Bain, SD; Celino, DL; Edwards, MW; Lantry, MM, 1993) |
| "Because PDGF may stimulate bone resorption in vitro, PDGF was administered with and without an antiresorptive agent (alendronate)." | ( Antoniades, HN; D'Andrea, M; Finkelman, RD; Hill, EL; Li, J; Lynch, SE; Martin, B; Mitlak, BH; Smith, T, 1996) |
| "Levels of the bone resorption marker, PYD, did not show any significant change, whereas BGP levels were drastically decreased 1 day after IA administration of corticosteroid, and then returned to pretreatment levels by day 14." | ( Dempster, DW; Emkey, RD; Lindsay, R; Lyssy, J; Shen, V; Weisberg, JS, 1996) |
| "By inhibiting bone resorption associated with the inflammatory response to implant particulates, pamidronate or other bisphosphonates may have clinical utility in the treatment or prevention or aseptic loosening." | ( Gonzales, JB; Horowitz, SM, 1996) |
| "Hydrogen peroxide stimulated bone resorption in a concentration-dependent manner in calvarial organ cultures with a maximal effect at 1 mumol/L (45Ca release; treated/control = 1." | ( Fraser, JH; Helfrich, MH; Ralston, SH; Wallace, HM, 1996) |
| "LTB4 increased osteoclastic bone resorption in vivo following local administration over the calvariae of normal mice and in vitro in organ cultures of neonatal mouse calvariae." | ( Bonewald, LF; Boyce, BF; Dallas, M; Garcia, C; Gilles, J; Mundy, GR; Qiao, M, 1996) |
| "The changes, however, in bone resorption and formation after bisphosphonate therapy are predictable, and their correct interpretation may allow a rational therapeutic approach applicable to the individual patient." | ( Frölich, M; Papapoulos, SE, 1996) |
| "Indices of bone resorption tended to decline and mineralized bone area tended to increase in insulin-treated animals." | ( Callon, KE; Cornish, J; Reid, IR, 1996) |
| "To inhibit bone resorption, a potent bisphosphonate, ibandronate (4 microg/mouse) was daily administered subcutaneously." | ( Bauss, F; De Clerck, YA; Dunstan, C; Mundy, GR; Sasaki, A; Williams, PJ; Yoneda, T, 1997) |
| "PYD and DPD are sensitive and specific bone resorption markers which demonstrate a slowing of bone resorption after palliative 89Sr-chloride therapy in patients with bone metastases." | ( Papatheofanis, FJ, 1997) |
| "A specific and responsive bone resorption marker can also be used to monitor and establish the short-term effectiveness of an antiresorptive therapy in the patient." | ( Eyre, DR, 1997) |
| "Differential effects on in vitro bone resorption were observed when the glucocorticoids, hydrocortisone and dexamethasone, were added to neonatal mouse calvariae treated with either parathyroid hormone (PTH), 1,25(OH)2-vitamin D3, all trans-retinoic acid (t-RA), or prostaglandin E2 (PGE2)." | ( Conaway, HH; Grigorie, D; Lerner, UH, 1997) |
| "Biochemical markers of bone resorption [urinary hydroxyproline, serum cross-linked carboxyterminal telopeptide of type I collagen, urinary cross-linked aminoterminal telopeptide of type I collagen (NTx)] and bone formation [serum bone-specific alkaline phosphatase, osteocalcin, and aminoterminal and carboxyterminal propeptide of type I procollagen] were assessed before treatment and at 6 and 12 months of the antiestrogen regimen." | ( Hietanen, P; Marttunen, MB; Tiitinen, A; Ylikorkala, O, 1998) |
| "A rapid and significant suppression of bone resorption was observed in all patients after intravenous treatment." | ( Hamdy, NA; Lycklama à Nijeholt, AA; Papapoulos, SE; Pelger, RC; Zwinderman, AH, 1998) |
| "They inhibit osteoclastic bone resorption and are established in the treatment of osteoporosis, Paget's disease of bone and especially in tumor bone disease." | ( Grauer, A; Ziegler, R, 1998) |
| "This increased bone resorption is inhibited by pamidronate without reducing G-CSF-induced HPC mobilization, suggesting that the activation of bone resorption after G-CSF administration is not the direct cause of HPC mobilization as initially hypothesized, but a parallel event." | ( Lévesque, JP; Moore, RJ; Morris, HA; Simmons, PJ; Takamatsu, Y; To, LB, 1998) |
| "We found that urinary markers of bone resorption are best measured on 2-hour fasting samples, because results on random urine showed poor precision and less decline with therapy." | ( Garber, J; Greenspan, SL; Lee, SL; Moses, AC; Rosen, HN; Ross, DS, 1998) |
| "Markers of bone resorption declined more slowly in patients treated previously with clodronate, although the average change in percent decrement from baseline in excess bAp as well as in excess of bone resorption markers was not different from that registered in untreated pagetic patients." | ( Casciari, C; Cristallini, S; Filipponi, P; Gregorio, F; Policani, G, 1998) |
| "The baseline levels of bone resorption markers were used to predict the probability of non-progressive bone disease or reduction in pain intensity during bisphosphonate therapy." | ( Engler, H; Koeberle, D; Riesen, WF; Senn, HJ; Thuerlimann, B, 1998) |
| "Measuring a bone resorption marker, ICTP, allows clinicians to monitor patients' responses to CAF therapy and may prevent prolonged ineffective therapy or unnecessary changes in therapy as a result of the flare phenomenon." | ( Koizumi, M; Matsumoto, S; Ogata, E; Takahashi, S; Yamashita, T, 1999) |
| "All markers of bone resorption decreased with initial treatment and decreased further with combination therapy (P < 0." | ( Kenny, AM; Pilbeam, CC; Prestwood, KM; Raisz, LG; Seibel, MJ; Thompson, DL, 1999) |
| "Treatment with minocycline reduced bone resorption modestly and stimulated bone formation substantially." | ( Barnes, J; Liang, CT; Martin, G; Seyedin, S; Wakisaka, A; Wechter, WJ; Williams, S; Zeng, QQ, 1998) |
| "Following treatment with the bone resorption inhibitor tiludronate, the morphometric parameters were significantly improved." | ( Barbier, A; de Vernejoul, MC; Lacheretz, F; Martel, C; Mocaer, G; Morieux, C; Murakami, H; Nys, M; Tirode, F, 1999) |
| "This study was designed to evaluate new bone resorption and tumour markers as possible alternatives to serial plain radiographs for the assessment of response to treatment." | ( Bastit, P; Coleman, R; Ford, J; Lacombe, D; Leonard, R; Michel, J; Mignolet, F; Nortier, J; Rose, C; Tubiana-Hulin, M; Vinholes, J; Wildiers, J, 1999) |
| "Bisphosphonates can inhibit bone resorption and have been successfully used clinically to treat osteoporosis and Paget's disease." | ( Agrawal, CM; Rubash, HE; Shanbhag, AS; Wang, X, 1999) |
| "The demonstration that cOPG can inhibit bone resorption suggests that this molecule may be useful in the treatment of diseases including hyperparathyroidism, humoral hypercalcemia of malignancy, osteoporosis, and inflammatory bone disease, which are characterized, in part, by increases in osteoclastic bone resorption." | ( Boone, T; Capparelli, C; Dunstan, CR; Lacey, DL; Lee, R; Morony, S; Shimamoto, G, 1999) |
| "A significant decrease in bone resorption rate and TRAP-positive osteoclast number was seen in rat bone marrow cultures and fetal mouse metacarpal cultures after antisense treatment." | ( Laitala-Leinonen, T; Löwik, C; Papapoulos, S; Väänänen, HK, 1999) |
| "Urinary markers of bone resorption, pyridinoline and deoxypyridinoline were measured before and at 4 weeks after radiotherapy for metastatic bone pain." | ( Folkes, LK; Hoskin, PJ; Regan, J; Stratford, MR; Yarnold, JR, 2000) |
| "There were no changes in bone resorption indices in either race upon 1,25(OH)2D administration." | ( Cosman, F; Gordon, S; Lindsay, R; Morgan, D; Nieves, J; Parisien, M; Shen, V, 2000) |
| "Treatment with 1,25(OH)(2)D(3) induced bone resorption similarly in PAI-1-/- and WT mice, as assessed by the increase in the urinary excretion of calcium (2." | ( Bouillon, R; Carmeliet, G; Daci, E; Moermans, K; Verstuyf, A, 2000) |
| "Markers of bone resorption are sensitive to changes in bone turnover induced by treatment." | ( Delmas, PD; Fontana, A, 2000) |
| "The suppressive effect on the bone resorption was not affected by treatment of caldecrin with phenylmethyl sulfonyl fluoride or by use of protease-deficient mutant caldecrins." | ( Fujimoto, K; Inaba, A; Katoh, S; Tomomura, A; Yamada, H, 2001) |
| "After treatment with NaF, bone resorption was not inhibited, but bone formation was significantly increased." | ( Huang, F; Jin, M; Ma, S; Tan, Y; Zhang, M; Zhao, H, 2000) |
| "Adjunctive anti-bone resorption therapy has become an important part of multiple myeloma (MM) treatment." | ( Choy, CG; Lyons, L; Michaeli, J; Niesvizkya, R; Siegel, D, 2002) |
| "This treatment significantly reduced bone resorption parameters (i." | ( Kaku, T; Koyama, H; Lau, KH; Nakade, O; Takada, Y, 2002) |
| "YH529 (YH), an inhibitor of bone resorption, or a vehicle (phosphate buffered saline=PBS) was administered daily starting 3 days before the commencement of tail-suspension." | ( Inazu, M; Ito, T; Kambe, F; Kanda, K; Kawano, S; Kurokouchi, K; Ohmori, S; Seo, H, 1998) |
| "Because on bone marker measurement bone resorption was increased and bone formation was decreased from baseline, treatment was switched to oral alendronate (5 mg/day, daily)." | ( Iwamoto, J; Takeda, T, 2002) |
| "This study shows that the bone resorption induced by immobilization in rats can be suppressed by treatment with S12911-2, resulting in partial reduction of the bone loss." | ( Deloffre, P; Hott, M; Marie, PJ; Tsouderos, Y, 2003) |
| "To test this hypothesis we assessed bone resorption and bone formation parameters in MSG-treated mice." | ( Armstrong, D; Elefteriou, F; Karsenty, G; Liu, X; Takeda, S, 2003) |
| "Accelerated bone resorption leading to osteopenia and osteoporosis has been noted in human immunodeficiency virus (HIV) seropositive, treatment-naive patients, but it may be greatly increased in incidence in those receiving highly active anti-retroviral therapies that incorporate certain protease inhibitors (PI)." | ( Fakruddin, JM; Laurence, J, 2003) |
| "Urine N-telopeptide, a bone resorption marker, levels declined in the treatment group more than in the control group (p = 0." | ( Aris, RM; Blackwood, AD; Brown, SA; Caminiti, M; Chalermskulrat, W; Guillen, U; Hecker, TM; Hensler, M; Lark, RK; Lester, GE; Neuringer, IP; Ontjes, DA; Renner, JB, 2004) |
| "By inhibiting bone resorption, bisphosphonate administration caused transient normalization of calcemia, associated with improved FIM, at a significantly higher level than in untreated patients (+16." | ( Ammann, P; Herter-Clavel, C; Lubrano, A; Rizzoli, R, 2003) |
| "Etidronate therapy inhibits bone resorption and improves calcium balance, and such therapy may prevent bone loss and reduce the risk of subsequent hip fracture." | ( Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K; Yasuda, H, 2004) |
| "In addition, bone resorption parameters were significantly lowered after administration of ZA." | ( Bergmeister, H; Gasser, J; Görtz, B; Hayer, S; Herrak, P; Kollias, G; Redlich, K; Reiter, E; Schett, G; Smolen, JS, 2004) |
| "Alendronate, an inhibitor of bone resorption, is widely used in osteoporosis treatment." | ( Gottschalk, FA; Maalouf, N; Odvina, CV; Pak, CY; Rao, DS; Zerwekh, JE, 2005) |
| "Trabecular bone resorption was decreased whereas bone formation was maintained or increased in the rats treated with alfacalcidol." | ( Healy, DR; Jee, WS; Li, M; Li, Y; Shen, VW; Simmons, HA; Su, M; Thompson, DD, 2004) |
| "Moreover, bone resorption by OCLs derived from MVNP-transduced CFU-GM treated with 10(-9) m 1alpha,25-(OH)(2)D(3) was dose-dependently inhibited by TEI-9647 (10(-9) m to 10(-6) m)." | ( Cornish, J; Cundy, T; Ishizuka, S; Kurihara, N; Reddy, SV; Roodman, GD, 2005) |
| "The inhibitory effect of TSH on bone resorption occurred only in postmenopausal women who showed low BMD and a high bone turnover rate as an effect of L-thyroxine suppressive therapy." | ( Amato, G; Biondi, B; Carella, C; Cioffi, M; Giustina, A; Iorio, S; Mazziotti, G; Pilla, P; Piscopo, M; Sorvillo, F, 2005) |
| "Rate of bone resorption after treatment seemed to be related to the amount of pamidronate retained." | ( Cremers, SC; den Hartigh, J; Gelderblom, H; Papapoulos, SE; Seynaeve, C; van der Rijt, CC; van Zuylen, L; Vermeij, P, 2005) |
| "To understand the bone resorption process on the basis of the morphology of bone resorption lacunae, the inner surface of parietal bones in juvenile mice was exposed with a treatment of ultrasonic waves or NaOCl treatment and examined by scanning electron microscopy (SEM)." | ( Abe, K; Ren, S; Takano, H, 2005) |
| "This study was conducted to identify bone resorption and anti-inflammatory effects with intermittent cyclical etidronate therapy (ICET) in patients with rheumatoid arthritis, and anti-inflammatory effect of etidronate in vitro." | ( Nagashima, M; Shue, G; Yamamoto, K; Yoshino, S, 2006) |
| "In the controlled study, bone resorption activity was higher after treatment discontinuation." | ( Glorieux, FH; Land, C; Munns, C; Rauch, F, 2006) |
| "In the present study, markers of bone resorption [urinary free pyridinoline (PYD), deoxypyridinoline (DPYD), N-terminal telopeptide of collagen I (NTX) and C-terminal telopeptide (serum crosslaps)] and of bone formation [bone alkaline phosphatase (BAP) and osteocalcin] were evaluated at diagnosis and after induction therapy in 40 patients (23M, 17F, median age = 53." | ( Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2006) |
| "These findings suggest that bone resorption in CsA-treated rats is induced by high-turnover osteoporosis and that bone remodeling activity may be activated by PTH." | ( Hayashi, N; Kataoka, M; Kido, J; Nagata, T; Seto, H; Shinohara, Y; Wada, C, 2006) |
| "We studied the bone resorption state in GC-treated CKD patients and the effects of bisphosphonate on S-NTX." | ( Fujii, N; Hamano, T; Horio, M; Imai, E; Isaka, Y; Ito, T; Moriyama, T; Nagasawa, Y; Okada, N, 2006) |
| "Significant alveolar bone resorption without alterations in vertebral bone mineral density indicated that lathyrogen administration for 40 days presumably has not caused systemic demineralization." | ( Acikgoz, G; Basoglu, T; Cetinkaya, BO; Firatli, E; Keles, G; Yapici, O, 2006) |
| "Pain scores and markers of bone resorption [C-telopeptide of collagen type-I (CTX), 5b-isoform of TRAP], bone formation [bone-alkaline phosphatase (bALP), osteocalcin (OC), C-telopeptide of procollagen type-I (CICP)], and osteoclast stimulators [sRANKL, osteoprotegerin (OPG), osteopontin] were also measured at baseline and before each treatment administration." | ( Anagnostopoulos, A; Kiamouris, C; Konstantopoulos, K; Spyropoulou, E; Stoupa, E; Terpos, E; Voskaridou, E, 2006) |
| "Trabecular bone resorption occurring from 1 to 2 weeks after the procedure was suppressed by a single injection of ED-71, but not 1alpha,25-(OH)2 D3, with treated mice exhibiting a reduction in osteoclast numbers, despite increases in osteoblast surface." | ( Asou, Y; Itoh, S; Muneta, T; Noda, M; Okuda, N; Shinomiya, K; Takeda, S, 2007) |
| "Bisphosphonates are inhibitors of bone resorption that are widely used to treat osteoporosis." | ( De Broe, M; Ketteler, M; Persy, V, 2006) |
| "Because bone resorption after SCI is very high, intravenous bisphosphonates and denosumab should be considered for the treatment of osteoporosis after SCI." | ( Dai, LY; Jiang, LS; Jiang, SD, 2006) |
| "Inhibition of bone resorption either by bisphosphonate (BP) treatment or by blocking RANKL signalling with osteoprotegerin (OPG) has been shown to reduce tumour burden in bone and inhibit bone destruction in murine xenograft models of breast cancer." | ( Blair, JM; Brennan, K; Dunstan, CR; Modzelewski, JR; Seibel, MJ; Zheng, Y; Zhou, H, 2007) |
| "Suppression of increased bone resorption is an important issue in treatment of post-menopausal osteoporosis." | ( Baylink, DJ; Itoi, E; Kasukawa, Y; Maekawa, S; Miyakoshi, N; Mohan, S; Nozaka, K; Srivastava, AK, 2007) |
| "The effect of risedronate treatment on bone resorption was investigated quantitatively by measuring N-telopeptide levels in urine of patients with hip fracture." | ( Altintaş, F; Beyzadeoğlu, T; Eren, A; Güven, M; Ozkut, AT, 2007) |
| "Bisphosphnates inhibit osteoclastic bone resorption and have been widely used for the treatment of osteoporosis." | ( Suzuki, Y, 2007) |
| "Bisphosphonates, potent inhibitors of bone resorption, are recommended as the most effective therapy and have been approved for treatment of hypercalcemia in myeloma." | ( Abe, M, 2007) |
| "Percent eroded surface, bone resorption and formation were suppressed by alfacalcidol treatment." | ( Chen, H; Jee, WS; Li, M; Liu, X; Setterberg, RB; Tian, X, 2008) |
| "We measured next the levels of two bone resorption markers in patients during the 3 days following five and seven therapeutic bortezomib administrations, respectively." | ( Andersen, TL; Boissy, P; Delaissé, JM; Kupisiewicz, K; Lund, T; Plesner, T, 2008) |
| "Low and high levels of bone resorption were induced by osteoprotegerin (OPG) treatment or calcium deficient diet respectively." | ( Dunstan, CR; Fong-Yee, C; Modzelewski, JR; Seibel, MJ; Zheng, Y; Zhou, H, 2008) |
| "The decreased bone resorption in response to GLP-2 injections cannot be elicited in SBS patients and therefore precludes treatment of their osteopenia with GLP-2." | ( Gottschalck, IB; Hartmann, B; Henriksen, DB; Holst, JJ; Jeppesen, PB, 2008) |
| "At T3, test sites treated showed less bone resorption compared with controls." | ( Cei, S; Gabriele, M; Graziani, F; La Ferla, F; Rosini, S, 2008) |
| "Untreated minipigs displayed a deep bone resorption pit, beneath the graft region, filled with type I collagen tissue as determined through immunohistochemical staining." | ( Abe, Y; Li, J; Masuda, K; Muehleman, C; Pfister, B; Phipps, R; Sah, RL, 2009) |
| "Interestingly, markers of bone resorption (TRAP5 RNA and serum levels) were decreased in diabetic mice by leptin treatment." | ( McCabe, LR; Motyl, KJ, 2009) |
| "Drugs that inhibit bone resorption constitute the mainstay for the treatment of postmenopausal osteoporosis." | ( Body, JJ, 2008) |
| "To slow down the process of induced bone resorption, OPG was administered and the effect was measured quantitatively by weighing the mass of the induced ossicle after hydrolysis of soft tissues surrounding the induced ossicles." | ( Kochanowska, I; Ostrowski, K; Pieńikowski, M; Włodarski, KH, 2004) |
| "HSP60 potentiated OC formation and bone resorption, and pretreatment with HSP60-blocking Ab markedly reduced the potentiation of OC formation and bone resorption by IL-1beta- and TNF-alpha." | ( Kim, GS; Kim, HH; Kim, YS; Koh, JM; Lee, KU; Lee, MS; Lee, SH; Lee, YS; Park, SH, 2009) |
| "In the treated group, bone resorption was reduced and remained reduced up to 12 months." | ( Bubbear, JS; Ferguson-Pell, M; Gall, A; Keen, RW; Middleton, FR; Swaminathan, R, 2011) |
| "Targeting bone resorption might therefore provide an approach to the treatment of high bone resorbing forms of OA." | ( Cohen-Solal, ME; Ea, HK; Funck-Brentano, T; Geoffroy, V; Hannouche, D; Kadri, A; Lin, H; Lioté, F; Marty, C, 2010) |
| "ODN effects were reversible: bone resorption increased transiently and BMD decreased following treatment discontinuation." | ( Bone, HG; DaSilva, C; Eisman, JA; Hosking, DJ; Hustad, CM; Ince, BA; Lombardi, A; McClung, MR; Petrovic, R; Reid, IR; Resch, H; Rizzoli, R; Santora, AC; Verbruggen, N, 2011) |
| "Thalidomide decreases bone resorption regardless of treatment response." | ( Bao, L; Huang, XJ; Lai, YY; Lu, J; Lu, XJ; Zhang, XH; Zhu, HH, 2011) |
| "In summary, ODN treatment inhibits bone resorption by blocking degradation of demineralized collagen in the resorption lacunae, and retarding transcytosis for further processing of degraded proteins." | ( Duong, LT; Leung, P; Masarachia, PJ; Pickarski, M; Zhuo, Y, 2011) |
| "Osteoclasts are primary bone resorption cells and intervention in osteoclast activation is considered an effective therapeutic approach to treatment of bone diseases involving osteoclasts." | ( Bo, M; Die, L; Li, T; Xing, L; Yan, P, 2011) |
| "Consequently, it also reduced the bone resorption marker, pyridinoline, in dexamethasone-treated adrenalectomised rats (2." | ( Faizah, O; Farihah, HS; Nazrun, SA; Nirwana, SI; Norazlina, M; Norliza, M; Suhana, MR, 2011) |
| "The decrease in PTH and the marker of bone resorption observed after the SrR administration is comparable to the decrease observed after the calcium administration in young adults." | ( Franek, T; Maresova, KB; Stepan, JJ; Vondracek, T, 2011) |
| "Compared to the OVX rats, levels of bone resorption markers (fragments of C-telopeptides of type I collagen) and bone formation markers (alkaline phosphatase and osteocalcin) decreased significantly in the treated rats." | ( Hsu, LH; Lin, FH; Lu, DH; Wang, CC; Wu, CC; Yang, KC, 2012) |
| "In view of the importance of bone resorption in mediating tooth movement, the aim of this study was to establish if alterations in the osteoclast-specific bone marker tartrate-resistant acid phosphatase (TRACP) 5b could be detected in the sera of patients undergoing orthodontic treatment." | ( MacLaine, JK; Meikle, MC; Rabie, BM; Tang, SJ; Wong, RW, 2013) |
| "Although 1,25(OH)₂D₃ stimulates bone resorption in vitro, treatment in vivo can prevent bone loss and fracture through several potential mechanisms." | ( Stern, PH; Yoshida, T, 2012) |
| "To assess correlations between a bone resorption marker and the structural geometry of the proximal femur in raloxifene-treated postmenopausal women with osteoporosis." | ( Iba, K; Takada, J; Yamashita, T; Yoshizaki, T, 2012) |
| "Transient bone resorption was only observed in the distal femoral sites treated with 4." | ( Li, XJ; Seeherman, HJ; Smith, E; Wozney, JM, 2012) |
| "Both reduction of bone resorption and stimulation of focal bone formation were more clearly observed in the eldecalcitol-treated rats than in the calcitriol-treated rats." | ( Amizuka, N; Saito, H; Takeda, S, 2013) |
| "The level of bone resorption marker (CL) dropped within 3 months after the onset of therapy (p<0." | ( Kiriliuk, IN; Kochetkova, EA; Semisotova, EF, 2012) |
| "Biomarkers of bone resorption: urinary DPYR, serum CTx, serum NTx, urinary Ca, and urinary P, at baseline after 4 weeks of treatment were changed by -13." | ( Cho, HR; Choi, IS; Choi, JS; Kim, JD; Kim, JW; Park, MY, 2013) |
| "However, their relative effects on bone resorption and formation, and how quickly the effects resolve after treatment cessation, are uncertain." | ( Boonen, S; Deacon, S; Eastell, R; Kuwayama, T; Nagase, S; Ohyama, M; Small, M; Spector, T, 2014) |
| "Reversal of bone resorption was observed in TME treated group of mice." | ( Balakrishnan, B; Chiplunkar, SV; Indap, MM; Krishna, CM; Singh, SP, 2014) |
| "Osteoclasts are unique cells capable of bone resorption and therefore have become a major target in osteoporosis treatment strategies." | ( Amling, M; Busse, B; Jobke, B; Milovanovic, P, 2014) |
| "Acteoside pretreatment also prevented bone resorption by mature osteoclasts in a dose-dependent manner." | ( Kook, SH; Lee, JC; Lee, KS; Lee, SY; Yi, SH, 2013) |
| "The flow chart of the measurement of bone resorption markers and bone formation markers when selecting drug treatment for osteoporosis, the measurement of ucOC and bone resorption markers when selecting drug treatment in osteoporosis, and the evaluation of therapeutic effects of bone antiresorption drugs using bone resorption markers were corrected newly in the guideline 2012 edition." | ( Miura, M, 2014) |
| "Consequently, the levels of bone resorption markers, tartrate-resistant acid phosphatase 5b (TRACP-5b) and serum type-I collagen crosslinked N-telopeptide (sNTX), significantly decreased after denosumab treatment, while the levels of bone formation markers, osteocalcin (OC) and bone-specific alkaline phosphatase (BAP), showed no apparent changes." | ( Hashimoto, A; Horiguchi, H; Ibata, S; Iyama, S; Kamihara, Y; Kato, J; Kobune, M; Ono, K; Sato, T; Takada, K; Takimoto, R; Tatekoshi, A, 2014) |
| "Because bone resorption is largely unaltered, OSM could represent a new anabolic treatment for unconsolidated bone fractures." | ( Amiaud, J; Berreur, M; Blanchard, F; Boutet, MA; Brounais-Le Royer, B; Gamblin, AL; Guihard, P; Heymann, D; Layrolle, P; Rédini, F; Renaud, A, 2015) |
| "Additionally, femoral, tibia, and L4 bone resorption was decreased in OVX induced control rats treated with the RC:PCP 2:1 mixture (60 and 120 mg/kg), respectively, compared with OVX control rats." | ( Choi, BR; Choi, SH; Han, CH; Kang, SJ; Kim, DC; Kim, SH; Ku, SK; Lee, YJ; Park, HR; Park, SJ; Song, CH; Yi, HY, 2015) |
| "OPG treatment lowered bone resorption rates and completely prevented bone loss during lactation but, surprisingly, did not decrease osteoclast numbers." | ( Ardeshirpour, L; Dann, P; Dumitru, C; Kim, W; Kostenuik, P; Sterpka, J; VanHouten, J; Wysolmerski, J, 2015) |
| "Drugs that inhibit bone resorption ('anti-resorptives') continue to dominate the therapy of bone diseases characterized by enhanced bone destruction, including Paget's disease, osteoporosis and cancers." | ( Russell, RG, 2015) |
| "Bone formation independent of bone resorption (a process known as 'minimodeling') was not changed in vehicle treated OVX rats despite the increase in bone turnover." | ( Bauss, F; Endo, K; Hashimoto, J; Sakai, S; Shimizu, M; Shimonaka, Y; Sugimoto, M; Takeda, S; Yogo, K, 2015) |
| "Further, the bone resorption activity of mature osteoclast treated with crocin was assessed by pit assay." | ( Fu, L; Jiao, Y; Pan, F, 2017) |
| "Within 6 months of treatment, bone resorption decreased, whereas RANK-L/OPG changes were inconsistent." | ( Constantin, T; Ioachimescu, AG; Ioachimescu, OC; Oyesiku, NM; Ritchie, J; Shah, R; Tangpricha, V, 2017) |
| "The frequency distribution of the bone resorption marker urinary deoxypyridinoline crosslinks (uDPD), was obtained retrospectively from 211 osteoporotic women attended at an academic hospital endocrine clinic, treated for >2 years with oral bisphosphonates." | ( Liel, Y; Plakht, Y; Tailakh, MA, 2017) |
| "We also observed higher levels of bone resorption and oxidative stress when iron was administered." | ( Chen, B; Fei, B; Jiang, Y; Sun, J; Wang, X; Xu, Y; Zhang, H; Zhang, P, 2018) |
| "Bisphosphonates (BP) are inhibitors of bone resorption and are used to treat postmenopausal osteoporosis." | ( Hauser, M; Hofstetter, W; Keller, I; Siegrist, M, 2018) |
| "The number of osteoclasts, the ratio of bone resorption pits, and the level of C-terminal cross-linked telopeptide of type I collagen (CTX) were significantly lower in LPS- and exendin-4-coadministered mice than in mice administered with LPS alone." | ( Ishida, M; Kimura, K; Kishikawa, A; Kitaura, H; Ogawa, S; Qi, J; Shen, WR; Shima, K; Sugisawa, H, 2018) |
| "A remarkable decrease in the bone resorption activity of osteoclasts was also noticed upon ferulic acid treatment." | ( Doss, HM; Ganesan, R; Rasool, M; Samarpita, S, 2018) |
| "Osteoclast number and bone resorption were significantly lower in mice that underwent LPS and DPP-4 inhibitor co-administration than in those that underwent LPS administration alone." | ( Ishida, M; Kimura, K; Kishikawa, A; Kitaura, H; Marahleh, A; Noguchi, T; Ogawa, S; Ohori, F; Qi, J; Shen, WR; Shima, K, 2019) |
| "While CIA rats displayed increased bone resorption and decreased bone formation, perindopril treatment almost completely abrogated the RAS-mediated osteopenia, indicating that inhibition of ACE reduced the joint damages in rats." | ( Kou, J; Li, H; Ren, Y; Wang, C; Wang, Y; Zhang, H; Zhang, Y, 2018) |
| "Thus, inhibition of osteoclastic bone resorption and regulation of the bone microenvironment are vital treatment strategies for osteoporosis." | ( Chen, X; Guo, S; Li, S; Liu, B; Liu, T; Ouyang, Z; Peng, D; Shen, Y; Wan, L; Yin, Z; Zhang, Q; Zhu, W, 2019) |
| "To induce bone resorption, LPS was administered at 10 mg/kg per injection." | ( Guo, K; Liu, ZL; Wang, WC; Xu, WF; Yu, SQ; Zhang, SY, 2019) |
| "Both treatments reduced bone resorption parameters, with Aln demonstrating a stronger inhibitory effect than SrR." | ( Chen, R; He, H; Ma, C; Shi, C; Sun, B; Wu, H; Zhang, Y, 2021) |
| "F-actin ring formation and increased bone resorption confirmed that osteoclasts treated with 6-shogaol were mature and functional." | ( Chen, JJ; Ningjuan, O; Shen, G; Trotman, CA; Van Dyke, TE; Yuan, H; Zhu, X, 2021) |
| "Osteoclasts are the major players in bone resorption and have always been studied in the prevention and treatment of osteoporosis." | ( Huang, JM; Lu, SY; Wang, CZ; Wang, Z; Yan, ZQ, 2021) |
| "Notably, bone resorption activity was found to be retained after GSB treatment, which would be beneficial for maintaining normal bone remodeling." | ( Chang, CY; Dharini, KK; Hong, JT; Li, CY; Lin, MD; Lin, WY; Peng, CH, 2022) |
| "The number and extent of bone resorption pits from ex vivo studies were markedly reduced with GaMH treatment." | ( Czech, T; Ghanta, P; Hessel, E; Oyewumi, MO; Oyewumi, O; Winschel, T, 2023) |
| "Cathepsin K, which is involved in bone resorption, is a good target for treating osteoporosis, but no clinically approved medicine has been developed." | ( Irie, K; Ito, M; Nagao, M; Nishino, K; Otsuka, T; Sato, S; Yamamoto, K, 2023) |